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Abstract
 
Allergic asthma is an inflammatory lung disease initiated and directed by T helper cells type 2
(Th2). The mechanism involved in generation of Th2 responses to inert inhaled antigens,
however, is unknown. Epidemiological evidence suggests that exposure to lipopolysaccharide
(LPS) or other microbial products can influence the development and severity of asthma.
However, the mechanism by which LPS influences asthma pathogenesis remains undefined.
Although it is known that signaling through Toll-like receptors (TLR) is required for adaptive
T helper cell type 1 (Th1) responses, it is unclear if TLRs are needed for Th2 priming. Here,
we report that low level inhaled LPS signaling through TLR4 is necessary to induce Th2 re-
sponses to inhaled antigens in a mouse model of allergic sensitization. The mechanism by
which LPS signaling results in Th2 sensitization involves the activation of antigen-containing
dendritic cells. In contrast to low levels, inhalation of high levels of LPS with antigen results in
Th1 responses. These studies suggest that the level of LPS exposure can determine the type of
inflammatory response generated and provide a potential mechanistic explanation of epidemio-
logical data on endotoxin exposure and asthma prevalence.
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Introduction
 
Asthma is a pulmonary inflammatory disease believed to be
due to aberrant Th2 immune responses to commonly in-
haled antigens (1). Only a subset of people exposed to these
aeroallergens, however, develop pathological Th2 re-
sponses, and this process is not well understood. In particu-
lar, the role of adjuvants and the innate immune system in
the induction of Th2 responses is unclear.
Respiratory infections have been linked to asthma in
both a preventative and facilitating role, implicating Toll-
like receptor (TLR) signaling in regulation of Th2-driven
airway disease (2). Of particular interest is LPS, a cell wall
component of Gram-negative bacteria that is ubiquitous in
the environment, including household dusts. LPS activates
cells through TLR4 with the accessory proteins CD14 and
LPS binding protein (3), signaling through a common
adaptor protein MyD88. This results in the transcription of
several activation markers including MHC II and B7 mole-
cules and the production of IL-1, IL-12, and TNF-
 
  
 
(3).
The role of endotoxin exposure in asthma development in
children has been controversial, with studies indicating ei-
ther a protective role through Th1 induction or an exacer-
bating effect on asthma severity (1, 4, 5). It has been specu-
lated that the opposing roles of LPS might be explained by
differences in exposure levels (6). However, these studies
did not address whether the association of household LPS
levels with asthma severity is a result of enhanced allergen
sensitization or direct irritant effects of LPS on previously
sensitized individuals (4, 6). Our objective was to assess if
LPS affects Th2 sensitization to aeroallergens and if the
amount of LPS exposure affects the disease phenotype.
It is now clear that Th1 adaptive immune responses re-
quire TLR signals (7). However, Th2 priming is thought
to occur either as a default pathway in the absence of TLR
signaling or by a currently unidentified Th2-type activating
receptor(s) (3). Therefore, the role a microbial adjuvant
such as LPS plays in Th2 aeroallergen sensitization at the
site of natural exposure, namely the lung, is unknown.
To directly address the role of LPS as an adjuvant for
Th2 sensitization in the induction of allergic airway re-
sponses, we used a murine model of Th2 pulmonary in-
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flammation in which priming occurs after antigen inhala-
tion without the use of alum. We show that Th2
sensitization occurs only if inhaled allergens are encoun-
tered with LPS, signaling through TLR4. Furthermore,
different doses of LPS induce distinct subsets of Th cells
and therefore distinct types of inflammatory responses.
 
Materials and Methods
 
Animals.
 
BALB/cJ (WT) and C.C3H-
 
Tlr4
 
Lps-d 
 
(TLR4d) mice
were purchased from The Jackson Laboratory. BALB/cAnNCr
mice were purchased from the National Cancer Institute. 6–10-
wk-old female mice were used in all experiments with three or
four mice per group.
 
Sensitization Protocols.
 
Mice were anesthetized with methoxy-
flurane (Metofane) and then sensitized intranasally with 100 
 
 
 
g
OVA (Grade V; Sigma-Aldrich) in 50 
 
 
 
l PBS on days 0, 1, and 2 as
previously described (8). For Fig. 3, we sensitized WT or TLR4d
mice intraperitoneally with 100 
 
 
 
g OVA in 2 mg aluminum hy-
droxide (Pierce Chemical Co.) in a total volume of 0.25 ml.
 
Airway Challenge.
 
Mice were challenged on days 14, 15, 18,
and 19 intranasally with 25 
 
 
 
g OVA and killed on day 21. We
confirmed that TLR4d and WT mice inhaled the antigen solu-
tion equally by administering Evan’s Blue (Sigma-Aldrich) intra-
nasally (9).
 
LPS Depletion and Measurement.
 
Endotoxin Detoxi-Gel™
(Pierce Chemical Co.) was used according to the manufacturer’s
instructions to remove 
 
 
 
99% of the contaminating LPS in the
administered OVA solution (resulting in a total dose 
 
 
 
0.001 
 
 
 
g
LPS during priming), which was measured by limulus amebocyte
assay (BioWhittaker).
 
Analysis of Bronchoalveolar Lavage (BAL).
 
Mice were killed
and BAL inflammatory cells were obtained as previously de-
scribed (10). We determined statistical significance using an un-
paired Student’s 
 
t
 
 test.
 
Lung Histology.
 
Paraffin-embedded coronal lung sections
were prepared as previously described (8) and stained with hema-
toxylin and eosin (H&E) or periodic acid-Schiff (PAS). All im-
ages are at 100
 
 
 
.
 
Determination of Serum Antibody Concentration.
 
Serum was ob-
tained on day 21 for measurement of OVA-specific IgE (11),
IgG1, and IgG2a (8) antibodies by ELISA as previously described.
Hyperimmune serum from OVA/alum immunized BALB/c mice
was used for IgE standard and set at 500 U/ml. Levels of detection
were 125 ng/ml (IgG1), 16 U/ml (IgE), and 81 U/ml (IgG2a).
 
Lymph Node Cytokine Production.
 
Mice were sensitized and
challenged with either OVA (WT or TLR4d) or PBS (WT) and
on day 21, mediastinal LN cells were isolated and stimulated in
vitro with 200 
 
 
 
g/ml OVA and syngeneic T cell–depleted sple-
nocytes. Cytokines in culture supernatants were measured using
commercially available ELISA kits (R&D Systems). Levels of
detection were 25.0 pg/ml (IL-4), 125.0 pg/ml (IL-5), and 1.9
ng/ml (IFN-
 
 
 
).
 
Serum and Bone Marrow–derived Dendritic Cell (BMDC) IL-12
Detection and BMDC Activation Markers.
 
Serum from mice was
obtained 4 h after the third inhalation of OVA with high or low
dose LPS and measured p70 levels using commercially available
ELISA kits (R&D Systems). For in vitro studies, BMDCs were
cultured as previously described (12) from TLR4d and WT mice.
On day 9 of culture, we added 100 
 
 
 
g/ml OVA, 100 ng/ml
TNF-
 
 
 
, or 50 ng/ml LPS and harvested cells and supernatant at
12 h. p70 level of detection was 7.8 pg/ml. After Fc receptor
blocking with 24G2, CDllc
 
hi 
 
(HL3) cells were evaluated by
FACS
 
® 
 
for MHC II (2G9) and B7.2 (GL1; BD Biosciences).
 
Dendritic Cell (DC) Migration Studies.
 
0.5 mg FITC-OVA
(Molecular Probes) was administered intranasally with low dose
(0.1 
 
 
 
g) LPS on days 0, 1, and 2 with or without 2 
 
 
 
g TNF-
 
 
 
on day 1. On day 3, we harvested and pooled the draining LNs in
each group and blocked Fc receptors and then stained them with
anti-CD11c fluorochrome.
 
Results
 
Dose of LPS Determines Type of Immune Response Gener-
ated to Inhaled Antigen.
 
We have previously shown that sen-
sitization of mice by exposure to inhaled OVA leads to ro-
bust pulmonary Th2 responses (8). To test the role of LPS
in these responses, we sensitized mice by intranasal expo-
sure to OVA depleted of contaminating LPS (
 
 
 
0.001 
 
 
 
g)
or OVA with a high (100 
 
 
 
g) or low (0.1 
 
 
 
g) dose of LPS.
These low and high doses of LPS are analogous to reported
endotoxin levels of samples from homes of atopic versus
nonatopic children, respectively (5). Mice exposed to LPS-
depleted OVA showed no airway inflammatory responses
after challenge with inhaled antigen (Fig. 1 A) and had total
BAL cell numbers equivalent to PBS controls. In contrast,
mice sensitized with OVA containing low dose LPS dem-
onstrated significant increases in total BAL cell numbers as
well as lung tissue infiltrates and airway mucus secretion
(Fig. 1, A and B). Both airway and tissue infiltrates were
dominated by eosinophils, consistent with Th2-mediated
inflammation. Draining lymph node (DLN) IL-5 and IL-
13 production confirmed the Th2 nature of the inflamma-
tory response (Fig. 1 C). Mice exposed to PBS or low dose
LPS alone did not generate pulmonary inflammation after
OVA challenge (Fig. 2 A).
As LPS is known to be a potent inducer of IL-12 pro-
duction from APCs in vitro, it might be expected to pref-
erentially stimulate Th1 responses. Therefore, we tested
whether the surprising induction of Th2 responses was a
result of the low dose of LPS exposure. Use of a high dose
of LPS during intranasal OVA priming resulted in a Th1-
associated response dominated by neutrophils and an ab-
sence of airway mucus production in the lung (Fig. 1, A
and B; reference 10). IFN-
 
  
 
production from DLNs con-
firmed the induction of a Th1 response in high dose LPS-
exposed mice (Fig. 1 C). Serum antibody isotype patterns
in groups sensitized with OVA containing low versus high
dose LPS were also consistent with the generation of Th2
(high IgE and IgG1) versus Th1 (high IgG2a) immunity,
respectively (Fig. 1 D). Thus, no airway inflammatory re-
sponse was generated in mice that had been sensitized with
LPS-depleted OVA, whereas antigen-specific immune re-
sponses were induced in the presence of LPS with low and
high doses inducing Th2 or Th1 responses, respectively.
 
TLR4 Signaling Is Required for Th2 Priming to Inhaled An-
tigens.
 
The requirement for LPS in the generation of Th2
responses to inhaled antigen was confirmed in C.C3H-
 
Tlr4
 
Lps-d 
 
mice (13) expressing a nonfunctional TLR4
(TLR4d). When compared with WT, TLR4d mice ex- 
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posed to OVA in the presence of low dose LPS showed
marked reduction in airway inflammation (Fig. 2 A) and
DLN Th2 cytokine production (Fig. 3 B, I.N.). We ob-
tained similar results using C3H/HeJ mice. Th1 responses
initiated with high dose LPS were similarly abrogated in
TLR4d mice (not depicted).
These data support the observation that LPS is required
for the development of Th2 (and Th1) responses to inhaled
Figure 1. The dose of LPS inhaled with antigen determines the nature of the immune response generated. (A) BAL inflammatory cells of BALB/c mice
exposed to LPS-depleted OVA (open bars), OVA with low dose LPS (gray bars), or OVA with high dose Escherichia coli LPS (solid bars; Sigma-Aldrich) af-
ter challenge. Monocytes constitute the remainder of BAL cells (not depicted). Bars depict the mean   standard deviation. *, P   0.01 (eosinophils in de-
pleted vs. low LPS groups); **, P   0.01 (eosinophils in high vs. low LPS groups); ***, P   0.01 (number of neutrophils in high vs. low LPS groups). One
representative experiment of six is shown. (B) Representative lung sections stained with H&E or PAS at 100 . Arrows indicate areas or peribronchiolar
cellular infiltrate (H&E) or positive mucus staining (PAS). (C) Cytokine production from lung draining LNs in low (solid bars) and high (open bars) dose
LPS groups. One representative experiment of four is shown. ND, not detectable. (D) Serum antibodies of low ( ) and high ( ) dose LPS groups are
compared with pooled sera from naive BALB/c mice ( ). Line depicts the mean. P   0.05 (LPS high vs. low dose) for IgG1, IgE, and IgG2a responses. 
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antigen. However, because LPS signaling is absent during
both sensitization and challenge in TLR4d mice, we next
asked at what stage LPS was required (6). To address this
question, Th2 cell–dependent OVA-specific antibody se-
cretion was measured. TLR4d mice demonstrated signifi-
cantly reduced OVA-specific IgG1 and no IgE or IgG2a
antibody responses (Fig. 2 B). In addition, there was evi-
dence of a reduced proliferative response in the lung DLN
of TLR4d mice as the cellularity after intranasal priming
was substantially diminished (5.9 
 
  
 
1.4 
 
  
 
10
 
6 
 
in WT vs.
2.3 
 
  
 
0.3 
 
  
 
10
 
6 
 
cells in TLR4d). Thus, there was evidence
of abrogated Th2 priming in TLR4d mice by systemic an-
tibody responses, DLN cellularity, lung inflammation, and
 
cytokine responses, consistent with defective T cell prim-
ing in the absence of LPS signaling.
 
TLR4d Mice Are Capable of Mounting Th2 Responses Using
the Adjuvant Aluminum Hydroxide.
 
To confirm that re-
cruitment pathways were intact in the lungs of TLR4d
mice, a TLR4 independent mechanism of Th2 priming was
used. Alum is a potent Th2 adjuvant that does not contain
microbial products and therefore should not involve TLR4
signaling to initiate immune responses. Therefore, TLR4d
and WT mice were immunized intraperitoneally with
OVA/alum or intranasally with OVA/LPS. 2 wk later,
both groups were challenged with inhaled antigen. TLR4d
mice were fully capable of initiating Th2 immunity in the
presence of a non-TLR4 adjuvant as evidenced by eosino-
philic BAL inflammation and Th2 cytokine responses in the
lung DLNs (Fig. 3, A and B). Thus, circumventing defi-
cient Th2 priming with the adjuvant alum results in equiv-
alent pulmonary inflammation in TLR4d and WT mice,
indicating that lung recruitment of eosinophils and lym-
phocytes is not impaired in TLR4d mice.
 
TNF-
 
  
 
Restores Pulmonary Inflammation in TLR4d Mice.
 
Adjuvants initiate adaptive immune responses by activating
DCs to present antigen in the context of MHC and costim-
ulatory molecules in the DLN (3). We hypothesized that if
we could induce DC maturation and migration in the ab-
sence of LPS adjuvant signals in TLR4d mice, we could re-
store T cell priming to inhaled antigen. TNF-
 
  
 
is both a
product of LPS-stimulated DCs and is known to activate
DCs. Using this cytokine to circumvent deficient matura-
tion signals by LPS, Th2 responses were completely restored
in TLR4d mice with administered TNF-
 
  
 
during sensitiza-
tion to inhaled antigen. This included airway inflammatory
responses (Fig. 4 A) and antibody responses (not depicted).
In addition, TNF-
 
  
 
administration restored DLN cytokine
production in TLR4d mice (116 
 
  
 
22 vs. 1516 
 
  
 
590 pg/
ml IL-5 and 524 
 
  
 
130 vs. 2225 
 
  
 
1186 pg/ml IL-13 in
TLR4d vs. TLR4d with TNF-
 
 
 
, respectively). These data
indicate that defective T cell priming can be overcome using
the LPS/TLR-induced cytokine TNF-
 
 
 
, implicating a role
for DC maturation and migration in the LPS adjuvant effect.
 
DC Maturation and Migration to the DLN Are Diminished
in TLR4d.
 
To test whether the role of low dose LPS with
OVA inhalation is to induce DC maturation and migration
Figure 2. TLR4 signaling is required for Th2 sensitization to inhaled
OVA. (A) BAL inflammatory cells of WT or TLR4d mice sensitized in-
tranasally with OVA with low dose LPS (0.1  g), or WT primed with
LPS alone, or PBS on day 21. Total bar height represents total cell num-
ber in BAL and error bars are based on total cell numbers. *, P   0.04
(total BAL cell number from TLR4d vs. WT). One representative exper-
iment of six is shown. (B) Serum antibody responses by ELISA on day 21
in WT ( ) and TLR4d ( ) mice compared with pooled naive serum
( ). P   0.05 (WT vs. TRL4d) for IgG1 and IgE responses.
Figure 3. TLR4d mice sensitized intraperitoneally with the adjuvant aluminum
hydroxide are capable of generating Th2 responses to OVA. (A) WT and TLR4d
were primed either intranasally with OVA or intraperitoneally with OVA in alum
and BAL was evaluated on day 21 after standard intranasal challenge. Stacked bars
of cell differential are shown. Total BAL cell number is represented by height of
stacked bars and standard error is based on total BAL number. *, P   0.005 (intranasally primed TLR4d vs. WT mice). Mice immunized intraperitoneally
with alum alone did not respond. (B) Cytokine production in pg/ml from DLN of intranasally or intraperitoneally primed WT (solid bars) or TLR4d
(open bars) mice. ND, not detectable. IFN-  was not detectable from cultures of WT or TLR4d mice primed intranasally or intraperitoneally with OVA
containing a low dose of LPS. One representative experiment of two is shown. 
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resulting in Th2 priming, we examined BMDCs for up-
regulation of MHC II and B7.2 in the presence or absence
of OVA/LPS or TNF-
 
 
 
. Although both activation markers
were up-regulated on DCs from WT mice in response to
either OVA/LPS or TNF-
 
 
 
, only TNF-
 
  
 
activated TLR4d
DCs in vitro (Fig. 4 B). We then used inhaled FITC-OVA
with low dose LPS to track migration in vivo of antigen-
containing DCs from the lung to the DLNs in WT versus
TLR4d mice. Although migration of CD11c
 
  
 
FITC
 
  
 
DCs
to DLNs was seen in WT mice, no significant antigen-
loaded DC migration occurred in TLR4d mice (Fig. 4 C).
Migration was restored in TLR4d mice upon the adminis-
tration of TNF-
 
  
 
with FITC-OVA. Thus, Th2 sensitiza-
tion is abrogated in the absence of TLR4-associated DC
migration. When migration to the DLN is restored using
TNF-
 
  
 
in TLR4d mice, Th2 responses are also restored.
 
DC IL-12 Production Differs after Exposure to Low and High
Doses of LPS.
 
LPS is known to induce both cell surface
DC maturation and the production of TNF-
 
 
 
, IL-1, and
IL-12 (3). As IL-12 is a potent Th1 skewing cytokine, we
hypothesized that differences in IL-12 production follow-
ing high versus low dose LPS inhalation with OVA might
explain the induction of Th1 versus Th2 responses, respec-
tively. To test this, serum IL-12 levels were analyzed. In
contrast to mice immunized with low dose LPS OVA, WT
mice immunized with high dose LPS OVA had signifi-
cantly higher levels of serum IL-12 (Fig. 5 A). In vitro eval-
uation of WT BMDC confirmed that only high dose LPS
Figure 4. Th2 pulmonary responses and DC activation in response to OVA with LPS are abrogated in TLR4d mice but can be restored with TNF- .
(A) We sensitized mice as before with half of groups receiving 2  g recombinant murine TNF-  (R&D Systems) intranasally on day 1. The number of
inflammatory cells recovered by BAL on day 21 is represented by the height of the stacked bars with error bars. *, P   0.001 (WT vs. TLR4d); **, P  
0.001 (TLR4d vs. TLR4d with TNF- ). (B) MHC II and B7.2 FACS® analysis of CDllchi BMDCs from WT or TLR4d stimulated for 12 h with PBS,
100  g/ml OVA/LPS, or 100 ng/ml TNF- . (C) Number of FITC  CDllc  cells in mediastinal LNs on day 3 after intranasal administration of
FITC-OVA with low dose (0.1  g) LPS (gray bars) with ( ) or without ( ) 2  g intranasal TNF-  (solid bars) on day 1. One representative experi-
ment of three is shown. *, P   0.01 (TLR4d   vs.   TNF- ).
Figure 5. Differential IL-12 production with high and low dose LPS.
(A) Serum IL-12 (p70) levels on day 2 of priming with inhaled OVA
containing either high (100  g) or low (0.1  g) levels of LPS. (B) IL-12
(p70) production from WT or TLR4d BMDCs after stimulation with
100  g/ml OVA with low dose LPS, 100 ng/ml TNF- , or high dose
(50 ng/ml) LPS for 12 h. ND, not detectable.1650 TLR4-dependent Th2 Sensitization to Inhaled Antigen
was capable of inducing IL-12 production, whereas OVA
(containing low dose LPS) did not (Fig. 5 B). These data
are consistent with the differential inflammatory response
observed in vivo (Th1 vs. Th2) and implicate an LPS
threshold requirement for IL-12 secretion. Interestingly,
TNF- , a cytokine capable of inducing DC maturation
and Th2 sensitization, was unable to induce IL-12 in WT
BMDCs. This is consistent with our observations that
TNF-  administration during priming was capable of res-
cuing Th2 responses in TLR4d mice without the induc-
tion of Th1 immunity (Fig. 4 A). As expected, no IL-12
was detected from TLR4d serum or BMDCs stimulated
with OVA, TNF- , or LPS.
Discussion
The results presented here support a model of sensitiza-
tion to inhaled inert proteins that requires LPS and the
TLR4 signaling pathway. In addition, the amount of LPS
present during sensitization determines whether Th1 or
Th2 immunity is observed. Although recent studies in
MyD88-deficient mice support a role for TLRs in the gen-
eration of Th1 responses to proteins, Th2 responses were
shown to be MyD88 independent, suggesting TLR signal-
ing is not important for the induction of Th2 cells (7).
However, recent work with MyD88-deficient DCs showed
that LPS stimulation induced IL-4 production with normal
up-regulation of costimulatory molecules resulting in a
Th2 skewing bias (14), suggesting that a MyD88-indepen-
dent pathway, TIRAP/MAL, is responsible for the ob-
served response. We might speculate that the threshold of
induction for these two signaling pathways of TLR4
requires distinct levels of signaling intensities, resulting in
differential effects on the adaptive immune response. The re-
sults from this study demonstrate the importance of TLR-
dependent adjuvants in the induction of Th2 responses and
the LPS dose differential of Th1/Th2 activation.
Another study using crystalline OVA in alum intraperi-
toneally suggested that TLR4-defective mice could not re-
call Th2-type inflammation to the lung (15). However, the
results presented here demonstrate that T cell priming us-
ing the adjuvant alum and cell recruitment to the lung are
intact in TLR4d mice, as would be expected from an LPS-
free, non-TLR–dependent adjuvant such as aluminum hy-
droxide (Fig. 3 A). This discrepancy may lie in the genetic
variation that could occur between the substrains of mice
used in their study.
The data reported here may help explain previously ob-
served differences in the response to inhaled protein, where
both tolerance and Th2 immunity have been seen (8, 9). It
is plausible that these differences are a result of varying lev-
els of LPS contamination and that one reason this protein
has been an effective antigen in many asthma models relates
to its inherent LPS contamination (16).
Various animal models indicate that exposure to micro-
bial sequences such as LPS can down-regulate Th2 pulmo-
nary responses (17). Epidemiological data in humans sup-
port a differential dose model with endotoxin exposure
correlated with both increased and decreased incidence of
lung disease and severity (1). Our data provide a model to
explain these conflicting findings in that OVA exposure in
the presence of high dose LPS fails to induce Th2 cells, but
instead induces both IL-12 production and a Th1 response.
By contrast, low dose LPS is not sufficient to induce Th1
cells but is required to induce Th2 inflammation. In the ab-
sence of LPS there is no significant lung response. Thus,
different levels of LPS exposure resulting in different Th
cell inflammatory responses might explain the discrepancies
in human studies. Recently discovered missense mutations
in human TLR4 could likewise provide an explanation for
the variability in human sensitization to ubiquitous aero-
allergens (18).
Respiratory syncytial virus (RSV) infections during
childhood have also been identified as a major risk factor
for the development of asthma (2). Although RSV is likely
to have multiple pathways of influencing asthma, it was re-
cently found that the innate immune response to RSV is
mediated by CD14 and TLR4 (19). This raises the ques-
tion of whether LPS has a unique role in asthma or if other
TLR ligands could induce Th2 sensitization.
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